Serum amyloid P component (SAP) modulates antidepressant effects through promoting membrane insertion of the serotonin transporter.

Humans Mice Animals Serotonin Plasma Membrane Transport Proteins / metabolism Serum Amyloid P-Component / metabolism Escitalopram Antidepressive Agents / pharmacology Selective Serotonin Reuptake Inhibitors / pharmacology

Journal

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907

Informations de publication

Date de publication:
02 2023
Historique:
received: 31 03 2022
accepted: 29 08 2022
revised: 24 08 2022
pmc-release: 01 02 2024
pubmed: 9 9 2022
medline: 24 1 2023
entrez: 8 9 2022
Statut: ppublish

Résumé

Serum amyloid P component (SAP) is a universal constituent of human amyloid deposits including those in Alzheimer's disease. SAP has been observed to be elevated in patients with depression, and higher SAP levels are associated with better response to the antidepressant escitalopram. The mechanisms underlying these clinical observations remain unclear. We examined the effect of SAP on serotonin transporter (SERT) expression and localization using Western blot, confocal microscopy, and positron emission tomography with the radioligand [

Identifiants

DOI: 10.1038/s41386-022-01449-4 PMID: 36076020 PMC: PMC9852251
pubmed: 36076020
doi: 10.1038/s41386-022-01449-4
pii: 10.1038/s41386-022-01449-4
pmc: PMC9852251
doi:

Substances chimiques

Serotonin Plasma Membrane Transport Proteins 0
Serum Amyloid P-Component 0
Escitalopram 4O4S742ANY
Antidepressive Agents 0
Selective Serotonin Reuptake Inhibitors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

508-517

Informations de copyright

© 2022. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.

Références

Front Mol Neurosci. 2016 Jan 26;9:4
pubmed: 26858599
Pharmacogenomics J. 2002;2(6):377-82
pubmed: 12629503
Brain Res. 1999 Sep 11;841(1-2):1-10
pubmed: 10546982
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Lancet. 2018 Apr 7;391(10128):1357-1366
pubmed: 29477251
Nat Med. 2010 Dec;16(12):1393-5
pubmed: 21113156
Neuroimage. 1997 Nov;6(4):279-87
pubmed: 9417971
PLoS One. 2014 May 30;9(5):e97540
pubmed: 24878716
Eur Neuropsychopharmacol. 2015 Oct;25(10):1532-43
pubmed: 26169573
Biol Psychiatry. 2016 Jan 1;79(1):32-8
pubmed: 26058706
IEEE Trans Med Imaging. 1997 Apr;16(2):145-58
pubmed: 9101324
Neuron. 2014 Dec 17;84(6):1302-16
pubmed: 25433637
Front Neurosci. 2019 Feb 12;13:91
pubmed: 30809118
Psychoneuroendocrinology. 2017 Apr;78:105-113
pubmed: 28187400
Neuron. 2002 Mar 28;34(1):13-25
pubmed: 11931738
J Psychiatr Res. 2022 Feb;146:172-178
pubmed: 34995992
Neuron. 2003 May 22;38(4):611-24
pubmed: 12765612
Science. 2003 Jul 18;301(5631):386-9
pubmed: 12869766
J Cell Sci. 2018 Sep 10;131(17):
pubmed: 30111583
EMBO J. 2007 Apr 18;26(8):2127-36
pubmed: 17380124
Neuroimage. 2008 Aug 1;42(1):60-9
pubmed: 18502665
Psychol Med. 1992 Nov;22(4):877-84
pubmed: 1488485
J Vis Exp. 2015 Mar 02;(97):
pubmed: 25867960
Cleve Clin J Med. 2008 Jan;75(1):57-66
pubmed: 18236731
J Vis Exp. 2012 Jan 29;(59):e3638
pubmed: 22314943
BJPsych Open. 2020 Jun 05;6(4):e60
pubmed: 32498754
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Mar;1865(3):158608
pubmed: 31891772
Biol Psychiatry. 2002 Aug 1;52(3):243-52
pubmed: 12182930
FASEB J. 2008 Jun;22(6):1702-14
pubmed: 18216289
J Clin Invest. 2020 Feb 3;130(2):877-889
pubmed: 31929189
Trends Cogn Sci. 2006 Apr;10(4):182-91
pubmed: 16530463
Nature. 1994 Jan 27;367(6461):338-45
pubmed: 8114934
Neuroimage. 1996 Dec;4(3 Pt 1):153-8
pubmed: 9345505
PLoS One. 2014 Apr 02;9(4):e93730
pubmed: 24695531
Nat Neurosci. 2010 Oct;13(10):1161-9
pubmed: 20877280
Neurosci Biobehav Rev. 2018 Jan;84:1-11
pubmed: 29128579
Shock. 2004 Feb;21(2):144-50
pubmed: 14752288

Auteurs

Ping Su (P)

Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China, Beijing, China.
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.

Shuxin Yan (S)

Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China, Beijing, China.
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.

Jian Yang (J)

Beijing AnDing Hospital, Capital Medical University, Beijing, China, Beijing, China.

Junchao Tong (J)

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
ORCID: 0000-0001-9299-0045

James Samsom (J)

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.

Fan You (F)

Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China, Beijing, China.

Yun Li (Y)

Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China, Beijing, China.

Qiuyue Chen (Q)

Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China, Beijing, China.

Anlong Jiang (A)

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.

Dongxu Zhai (D)

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.

Jiahao Chen (J)

Departments of Neurobiology and Pathology, Beijing Key Laboratory of Neural Regeneration and Repair, Capital Medical University, Beijing, 100069, China.

Zuoli Sun (Z)

Beijing AnDing Hospital, Capital Medical University, Beijing, China, Beijing, China.

Jingjing Zhou (J)

Beijing AnDing Hospital, Capital Medical University, Beijing, China, Beijing, China.

Min Liu (M)

Beijing AnDing Hospital, Capital Medical University, Beijing, China, Beijing, China.

Frank J S Lee (FJS)

Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.

Zhi-Qing David Xu (ZD)

Departments of Neurobiology and Pathology, Beijing Key Laboratory of Neural Regeneration and Repair, Capital Medical University, Beijing, 100069, China.

Xin Wang (X)

Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250021, China.

Neil Vasdev (N)

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Departments of Psychiatry, University of Toronto, Toronto, ON, Canada.

Albert H C Wong (AHC)

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Departments of Psychiatry, University of Toronto, Toronto, ON, Canada.
Departments of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.

Fang Liu (F)

Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China, Beijing, China. fang.liu@camh.ca.
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada. fang.liu@camh.ca.
Departments of Psychiatry, University of Toronto, Toronto, ON, Canada. fang.liu@camh.ca.
Departments of Physiology, University of Toronto, Toronto, ON, Canada. fang.liu@camh.ca.
Institute of Medical Science, University of Toronto, Toronto, ON, Canada. fang.liu@camh.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Serum amyloid P component (SAP) modulates...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Serum amyloid P component (SAP) modulates...
questionsmedicales.fr › Eucaryotes › Animaux › Serum amyloid P component (SAP) modulates...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Protéines transporteurs de solutés › Transporteurs de la sérotonine › Serum amyloid P component (SAP) modulates...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Glycoprotéines › Composant sérique amyloïde P › Serum amyloid P component (SAP) modulates...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Benzofuranes › Escitalopram › Serum amyloid P component (SAP) modulates...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Psychoanaleptiques › Antidépresseurs › Serum amyloid P component (SAP) modulates...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents sérotoninergiques › Inhibiteurs sélectifs de la recapture de la sérotonine › Serum amyloid P component (SAP) modulates...